Literature DB >> 6172031

Electrocardiographic changes evoked by ajmaline in chronic Chagas' disease with manifest myocarditis.

P A Chiale, J Przybylski, R A Laiño, M S Halpern, R A Sánchez, A Gabrieli, M V Elizari, M B Rosenbaum.   

Abstract

Conversion from Chagas' infection to chagasic myocarditis occurs slowly and the earliest signs of myocardial involvement are hard to define. To obtain new information on this difficult clinical problem, ajmaline was administered (1 mg/kg body weight intravenously) to 101 patients with Chagas' infection and to 46 patients without such infection (control group). In 3 patients in the control group left anterior hemiblock alone occurred whereas in the group with Chagas' infection, ajmaline caused the occurrence of right bundle branch block, left anterior hemiblock, or both, in 32 patients (31.6 percent), ventricular extrasystoles in 8 (7.9 percent) and ischemic ST-T changes in 7 (6.9 percent). Ajmaline may thus evoke the most typical electrocardiographic changes of chronic chagasic myocarditis in patients without signs of myocardial involvement or only minor nonspecific signs. A positive ajmaline test, defined in the present context as the occurrence of a fascicular block, ventricular arrhythmias or ischemic ST-T changes, may indicate the existence of localized areas of injured myocardial tissue, not enough to alter the electrocardiogram by itself, but able to give rise to severe abnormalities after exposure to the drug. The test may therefore be used as a nonspecific detector of myocardial damage, and thus may have a much broader scope of clinical application. In chronic Chagas' infection, the ajmaline test is a relatively simple and apparently safe procedure that may serve to unveil the earliest signs of chagasic myocarditis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6172031     DOI: 10.1016/0002-9149(82)90271-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Brugada phenocopy: new terminology and proposed classification.

Authors:  Adrian Baranchuk; Timothy Nguyen; Min Hyung Ryu; Francisco Femenía; Wojciech Zareba; Arthur A M Wilde; Wataru Shimizu; Pedro Brugada; Andrés R Pérez-Riera
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-08-13       Impact factor: 1.468

Review 2.  Is there an overlap between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy/dysplasia?

Authors:  Andrés Ricardo Pérez Riera; Charles Antzelevitch; Edgardo Schapacknik; Sergio Dubner; Celso Ferreira
Journal:  J Electrocardiol       Date:  2005-07       Impact factor: 1.438

3.  The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization.

Authors:  Arthur A M Wilde; Pieter G Postema; José M Di Diego; Sami Viskin; Hiroshi Morita; Jeffrey M Fish; Charles Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2010-07-24       Impact factor: 5.000

4.  The ajmaline test as a method to disclose latent experimental Chagas' heart disease.

Authors:  R B Bestetti; E G Soares; V N Sales-Neto; J S Oliveira
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

5.  Diagnostic dilemmas: overlapping features of brugada syndrome and arrhythmogenic right ventricular cardiomyopathy.

Authors:  Mark G Hoogendijk
Journal:  Front Physiol       Date:  2012-05-23       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.